Literature DB >> 26238641

Supplemental Oxygen Therapy for Patients with Chronic Obstructive Pulmonary Disease.

Igor Barjaktarevic1, Christopher B Cooper1.   

Abstract

Oxygen is necessary for aerobic metabolism. Since the human body cannot produce or store oxygen, a continuous and adequate delivery of oxygen needs to be secured by oxygen uptake from inhaled air via the respiratory system and oxygen delivery to body tissues via the circulation. Severely reduced lung function in advanced chronic obstructive pulmonary disease (COPD) may be a limiting factor for adequate oxygen uptake and patients with this disease may require supplemental oxygen therapy. While the methodology of oxygen delivery in home settings represents a continuously evolving field, oxygen therapy itself has been an integral part of the management of severely hypoxemic patients with COPD for more than 50 years despite the lack of full understanding of its effects and the relative paucity of clinical evidence supporting its use. In this article, we review the physiological effects and discuss the clinical benefits of oxygen therapy. We also evaluate the evidence supporting and arguing against its use in the published literature, discuss its risks and benefits, define criteria for prescribing oxygen therapy, and review methods of oxygen delivery in home settings. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2015        PMID: 26238641     DOI: 10.1055/s-0035-1556058

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  1 in total

1.  An inhibitor of RORγ for chronic pulmonary obstructive disease treatment.

Authors:  Harshada Desai; Megha Marathe; Varada Potdar; Prabhakar Tiwari; Ashwini Joshi; Malini Bajpai; Nagaraj Gowda; Pravin S Iyer; Sheetal R Kadam; Arti Rajesh Joshi; Abhay Kulkarni; Vikram Bhosale; Avinash Hadambar; Bhavik Lodhiya; Venkatesha Udupa; Dayanidhi Behera; Sachin S Chaudhari; Sanjib Das
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.